Patient with changes in mental status and motor dysfunction

Despoina Voultsinou, Triantafillos Gerukis, Panos Prassopoulos


Central Nervous System, Magnetic Resonance Imaging, Perfusion Imaging, Diffusion, Lymphoma, Multiple Sclerosis

Full Text:



Partovi S, Karimi S, Lyo JK, et al. Multimodality imaging of primary CNS lymphoma in immunocompetent patients. Br J Radiol 2014; 87(1036): 20130684.

Brandsma D, Bromberg JEC. Primary CNS lymphoma in HIV infection. Handbook of Clinical Neurology 2018; 152: 177-186.

Abddoli M, Freedman MS. Neuro-oncology dilemma: tumor or tumefactive demyelinating lesion. Mult Scler Relat Disord 2015; 4(6): 555-566.

Lin X, Yu WY, Liauw L, et al. Clinicoradiologic Features distinguish tumefactive multiple sclerosis form CNS neoplasms. Neurol Clin Pract 2017; 7(1): 53-64.

Hyland M, Bermel RA, Cohen JA, et al. Restricted diffusion preceding gadolinium enhancement in large or tumefactive demyelinating lesions. Neurol Clin practice 2013; 3(1): 15–21.

Mabray MC, Cohen BA, Villanueva-Meyer JE, et al. Performance of apparent Diffusion Coefficient Values and conventional MRI features in differentiating tumefactive demyelinating lesions from primary brain neoplasms. AJR Am J Roentgenol 2015; 205: 1075-1085.

Suh CH, Kim HS, Jung SC, et al. MRI findings in tumefactive demyelinating lesions: A systematic review and Meta –Analysis. AJNR 2018; (9): 1643-1649.

Parks NE, Bhan V, Shankar JJ. Perfusion imaging of tumefactive demyelinating lesions compared to high grade gliomas. Can J Neurol Sci 2016; 43: 316-318.

Cianfoni A, Niku S, Imbesi SG. Metabolite findings in tumefactive demyelinating lesions utilizing Short Echo Time Proton Magnetic Resonance Spectroscopy. AJNR 2007; (2): 272-277.

Algahtani H, Shirah B, Alassiri A. Tumefactive demyelinating lesions: A comprehensive review. Mult Scler Disod



  • There are currently no refbacks.